Mapping off-label use and reimbursement pathways for oncology drugs in The Netherlands: a cross-sectional observational study.
BACKGROUND Off-label use of anticancer medicines is common. Investigator-initiated trials evaluating off-label indications often do not result in label expansion. Additionally, off-label use is often considered when approved treatments are lacking or exhausted. Such use may lead to uncertain efficacy and safety and pos...